NasdaqGM - Nasdaq Real Time Price • USD
AC Immune SA (ACIU)
As of 2:36 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.15 | -0.22 | -0.73 | -0.23 |
| Low Estimate | -0.22 | -0.23 | -0.77 | -0.55 |
| High Estimate | -0.04 | -0.2 | -0.71 | 0.41 |
| Year Ago EPS | -0.23 | -0.22 | -0.7 | -0.73 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 3 |
| Avg. Estimate | 6.03M | 550k | 9.32M | 68.63M |
| Low Estimate | -- | -- | -- | 27M |
| High Estimate | 16.98M | 1.1M | 16.98M | 150.8M |
| Year Ago Sales | -- | 1.84M | 16.24M | 9.32M |
| Sales Growth (year/est) | -- | -70.10% | -42.60% | 636.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.21 | 0.03 | -0.12 |
| EPS Actual | -0.23 | -0.22 | -0.21 | -0.05 |
| Difference | 0.02 | -0.01 | -0.24 | 0.07 |
| Surprise % | 8.00% | -4.80% | -800.00% | 58.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.22 | -0.73 | -0.23 |
| 7 Days Ago | -0.11 | -0.21 | -0.71 | -0.07 |
| 30 Days Ago | -0.11 | -0.21 | -0.71 | -0.08 |
| 60 Days Ago | -0.2 | -0.2 | -0.59 | -0.26 |
| 90 Days Ago | 0 | 0 | -0.56 | -0.31 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACIU | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 34.80% | -- | -- | 1.30% |
| Next Qtr. | 0.00% | -- | -- | 10.60% |
| Current Year | -4.30% | -- | -- | 5.10% |
| Next Year | 68.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/7/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/28/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/1/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 4/19/2023 |
Related Tickers
CGTX Cognition Therapeutics, Inc.
2.0000
+7.53%
ADAG Adagene Inc.
2.6500
0.00%
ALZN Alzamend Neuro, Inc.
0.7195
+4.58%
CBUS Cibus, Inc.
15.95
-0.31%
ATHA Athira Pharma, Inc.
2.0650
-1.20%
ASLN ASLAN Pharmaceuticals Limited
0.4773
+4.86%
ANVS Annovis Bio, Inc.
11.78
+2.52%
MNPR Monopar Therapeutics Inc.
0.6500
+2.85%
KRON Kronos Bio, Inc.
0.9562
-0.40%
DSGN Design Therapeutics, Inc.
3.8150
-1.93%